Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.45 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | NCOA1 | Q15788 | 2/20 | 0.44 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27522822 | 0.86 | ALDH1A1 (0.47) | MAPTKDM4EPOLBMEN1KMT2A | |
| SCHEMBL128548 | 0.84 | NCF1 (0.56) | MAPTKDM4EMEN1KMT2ACYP3A4 | |
| SCHEMBL8194 | 0.77 | ALDH1A1 (0.67) | MAPTKDM4EPOLBMEN1KMT2A | |
| SCHEMBL30099834 | 0.77 | ALDH1A1 (0.67) | MAPTKDM4EPOLBMEN1KMT2A | |
| SCHEMBL198641 | 0.76 | MAPT (0.64) | MAPTKDM4EPOLBMEN1KMT2A | |
| SCHEMBL217044 | 0.75 | MAPT (1.00) | MAPTKDM4EPOLBMEN1KMT2A | |
| Formaldehyde SCHEMBL27344975 | 0.75 | ALDH1A1 (0.57) | MAPTKDM4EPOLBMEN1KMT2A | |
| SCHEMBL8384663 | 0.74 | MAPT (0.61) | MAPTKDM4EPOLBMEN1KMT2A | |
| SCHEMBL2714092 | 0.74 | MAPT (0.61) | MAPTKDM4EPOLBMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL3710107 | 0.74 | ALDH1A1 (0.63) | MAPTKDM4EPOLBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0973767-A1 | INDAZOLES OF CYCLIC UREAS USEFUL AS HIV PROTEASE INHIBITORS | Dupont Pharmaceuticals Company (US) | 2000-01-26 | — | — | EP | claimed |
| US-5985867-A | TREATING HIV INFECTION | DUPONT PHARMACEUTICALS COMPANY (US) | 1999-11-16 | — | — | US | claimed |
| WO-1998043969-A1 | INDAZOLES OF CYCLIC UREAS USEFUL AS HIV PROTEASE INHIBITORS | DUPONT PHARMACEUTICALS COMPANY (US) | 1998-10-08 | — | — | WO | claimed |
| EP-0118685-A1 | Propene derivatives and their use as plant growth inhibitors | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1984-09-19 | — | — | EP | claimed |
| EP-0117412-A1 | Propene derivatives and their use as plant growth inhibitors | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1984-09-05 | — | — | EP | claimed |
| EP-3029030-B1 | TETRAZOLINONE COMPOUND, AND USE THEREFOR | SUMITOMO CHEMICAL CO (JP) | 2019-09-04 | — | — | EP | disclosed |
| CN-109071535-A | N L RP3 modulators | 先天肿瘤免疫公司 | 2018-12-21 | — | — | CN | disclosed |
| US-9889115-B2 | Fitness assay and associated methods | BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2018-02-13 | — | — | US | disclosed |
| US-9512090-B2 | Tetrazolinone compound and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-12-06 | — | — | US | disclosed |
| US-9440958-B2 | Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases | INCYTE CORPORATION (US) | 2016-09-13 | — | — | US | disclosed |
| US-20160159755-A1 | TETRAZOLINONE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-06-09 | — | — | US | disclosed |
| EP-3029030-A1 | TETRAZOLINONE COMPOUND, AND USE THEREFOR | Sumitomo Chemical Company, Limited (JP) | 2016-06-08 | — | — | EP | disclosed |
| EP-1088098-A2 | FITNESS ASSAY AND ASSOCIATED METHODS | UNITED STATES OF AMERICA REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND SOCIAL SERVICES (US) | 2001-04-04 | — | — | EP | disclosed |
| EP-0973767-A1 | INDAZOLES OF CYCLIC UREAS USEFUL AS HIV PROTEASE INHIBITORS | Dupont Pharmaceuticals Company (US) | 2000-01-26 | — | — | EP | disclosed |
| WO-1999067254-A2 | MULTI-DRUG RESISTANT RETROVIRAL PROTEASE INHIBITORS AND USE THEREOF | THE UNITED STATES OF AMERICA REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1999-12-29 | — | — | WO | disclosed |
| WO-1999067417-A2 | FITNESS ASSAY AND ASSOCIATED METHODS | THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1999-12-29 | — | — | WO | disclosed |
| US-5985867-A | TREATING HIV INFECTION | DUPONT PHARMACEUTICALS COMPANY (US) | 1999-11-16 | — | — | US | disclosed |
| WO-1998043969-A1 | INDAZOLES OF CYCLIC UREAS USEFUL AS HIV PROTEASE INHIBITORS | DUPONT PHARMACEUTICALS COMPANY (US) | 1998-10-08 | — | — | WO | disclosed |
| EP-0118685-A1 | Propene derivatives and their use as plant growth inhibitors | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1984-09-19 | — | — | EP | disclosed |
| EP-0117412-A1 | Propene derivatives and their use as plant growth inhibitors | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1984-09-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160159755-A1 | TETRAZOLINONE COMPOUND AND USE THEREOF | CYP1A1, CASP1, TCOF1 | MAPT 2985/4885KDM4E 3200/4885POLB 4374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.